



Cornell Stamoran, Ph.D.

Vice President, Corporate Strategy & Govt. Affairs, Catalent, Inc.
Founder & Chair, Catalent Applied Drug Delivery Institute

Catalent Pharma Solutions

14 Schoolhouse Road
Somerset, NJ 08873
732.537.6408
908.313.0643

Cornell.stamoran@catalent.com

twitter @stamoran

General Background

Cornell Stamoran serves as Vice President of Corporate Strategy and Government Affairs for Catalent Inc (NYSE: CTLT) and is a founder and chair of Catalent's Applied Drug Delivery Institute. Cornell has worked in drug delivery for more than 30 years, spanning oral, injectable, respiratory, ophthalmic, and other routes of delivery, for drugs, biologics, cell and gene therapies, vaccines, and consumer health products. Cornell is a trustee of the Pharma/Biopharma Outsourcing Association, as well as current Treasurer and past Secretary; past board member and treasurer of the Controlled Release Society; and serves on the Editorial Advisory Board for several publications including *Drug Development and Delivery* magazine and several key industry conferences. Cornell has published more than three dozen articles on drug delivery, patient-focused drug design, and pharmaceutical outsourcing, and frequently speaks and posts on these topics. Cornell also serves on the cross-industry teams which negotiated GDUFA (II and III) and OMUFA (I and II) with the FDA.

CRS Vision

I believe that CRS occupies a unique place in the drug delivery ecosystem, where all who contribute to discovery, translation, and application of enhanced delivery approaches are welcome, and all steps in the process, from basic research through to production of advanced delivery forms for patients, are equally celebrated and embraced.

I believe we have a unique opportunity enhance the value we jointly create in drug delivery, greater than the sum of our two core practice areas, academia and industry. As a past CRS Treasurer and board member, and now as a potential Director at Large, I have and will continue to seek to build more bridges between these areas, to accelerate collaboration opportunities and ultimately accelerate translation of delivery innovations to approved patient treatments.

As a former CRS treasurer, I'm also passionate about ensuring that we maintain a strong financial foundation to sustain and extend CRS mission-driving activities. Given ongoing shifts in both research and industry funding, it's increasingly important for us to engage with current and new stakeholders, bringing new value to both members and corporate and other partners.